Oscotec wins Europe patent for BT-201 for treatment of arthritis

Published: 2010-03-16 06:56:00

Updated: 2010-03-16 06:56:00

Oscotec Inc., a local bone-related biopharmaceutical company, said on March 10 that it has recently won a patent of its anti-arthritis drug, BT-201, from the European Patent Office for the treatment of arthritis

The company said BT-201 is derived from natural substances to help regenerate cart...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK